Lupin today said that it has received final approval from the US health regulator to sell generic diabetes management drug Pioglitazone tablets in the American market.
Lupin said its US subsidiary, Lupin Pharmaceuticals Inc, has received final approval for its Pioglitazone tablets from the US Food and Drugs Administration to market the generic version of Takeda Pharmaceuticals USA Inc’s Actos tablets.
The company said in a BSE filing that its subsidiary will shortly commence marketing the product. The approval has been granted for tablets in strengths of 15 mg, 30 mg and 45mg.
“Lupin’s Pioglitazone tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings,” the company said.
As per IMS MAT December data, Actos tablets had annual US sales of $236 million.
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…